<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02827487</url>
  </required_header>
  <id_info>
    <org_study_id>Celecoxib IUD</org_study_id>
    <nct_id>NCT02827487</nct_id>
  </id_info>
  <brief_title>Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion</brief_title>
  <acronym>IUD</acronym>
  <official_title>Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion: A Double Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two hundred and ten women requesting IUD insertion will be randomly divided into three equal&#xD;
      groups. To ensure blinding the double dummy technique will be used in which group 1 will&#xD;
      receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally in addition to a placebo&#xD;
      similar to Celecoxib, group 2 will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in&#xD;
      addition to a placebo similar to Tramadol, and group 3 will received a placebo similar to&#xD;
      Tramadol in addition to a placebo similar to Celecoxib. All the drugs will be given 2 hour&#xD;
      before the procedure.&#xD;
&#xD;
      After insertion of the IUD the women's pain perception will be assessed using a visual&#xD;
      analogue scale (VAS) graduated from zero to 10 with zero corresponding to no pain and 10&#xD;
      corresponding to the worst possible pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intrauterine device (IUD) is a commonly used long-acting, effective and reversible method&#xD;
      of contraception. IUD insertion is usually associated with a variable degree of pain. The&#xD;
      majority of women experience mild pain or discomfort during IUD insertion, and some women may&#xD;
      experience severe pain. Nulliparous women, women who delivered only by cesarean section and&#xD;
      women remote from vaginal delivery are subgroups of women who experience more pain during IUD&#xD;
      insertion. Prophylactic pharmacological interventions for management of pain associated with&#xD;
      IUD insertion include nonsteroidal anti-inflammatory drugs (NSAIDs), opioid analgesics&#xD;
      including Tramadol. Tramadol hydrochloride is an orally active centrally acting synthetic&#xD;
      opioid. It is an atypical analgesic with a dual mechanism of action: serotonin and&#xD;
      norepinephrine reuptake inhibition and modest l-opioid agonist. It has a lower incidence of&#xD;
      respiratory depression, cardiac depression, side effects on smooth muscle and abuse potential&#xD;
      as compared to typical opioid agents. Cervical ripening with prostaglandins was suggested&#xD;
      facilitate the introduction of the IUD through the cervix, although at the cost of increased&#xD;
      pain due to uterine cramping.&#xD;
&#xD;
      The study objective is to compare the effectiveness and side effects of oral Tramadol 100mg&#xD;
      versus oral Celecoxib 200mg in reducing pain associated with operative outpatient&#xD;
      hysteroscopy in an attempt to find the most effective drug with the least possible side&#xD;
      effects to be used before IUD insertion.&#xD;
&#xD;
      Two hundred and ten women requesting IUD insertion will be randomly divided into three equal&#xD;
      groups. To ensure blinding the double dummy technique will be used in which group 1 will&#xD;
      receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally in addition to a placebo&#xD;
      similar to Celecoxib, group 2 will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in&#xD;
      addition to a placebo similar to Tramadol, and group 3 will received a placebo similar to&#xD;
      Tramadol in addition to a placebo similar to Celecoxib. All the drugs will be given 2 hour&#xD;
      before the procedure. An independent person will generate the allocation sequence using&#xD;
      computer generated random numbers.&#xD;
&#xD;
      The researchers will performed bimanual examination, introduce a speculum into the vagina and&#xD;
      sterilized the cervix with povidone iodine before inserting the IUD according to the&#xD;
      manufacturer recommendations.&#xD;
&#xD;
      After insertion of the IUD the women's pain perception will be assessed using a visual&#xD;
      analogue scale (VAS) graduated from zero to 10 with zero corresponding to no pain and 10&#xD;
      corresponding to the worst possible pain.&#xD;
&#xD;
      Quantitative data will be statistically represented in terms of mean ± standard deviation (±&#xD;
      SD) while categorical data will be represented as frequency and percentage. Comparison of&#xD;
      quantitative data will be done using ANOVA test for independent samples while categorical&#xD;
      data will be compared using Chi squared test or Fisher exact test when appropriate. A&#xD;
      probability value (p value) less than 0.05 will be considered significant.&#xD;
&#xD;
      To the best of the investigators' knowledge this is the first trial to investigate the role&#xD;
      of Celecoxib and oral Tramadol in reducing IUD insertion associated pain, with no previous&#xD;
      data to calculate the sample size with. Assuming that the response will be normally&#xD;
      distributed, the sample size is calculated to detect a mean difference of 1 unit between&#xD;
      Tramadol and Celecoxib pain scores during the procedure (lower difference are not considered&#xD;
      clinically relevant) using VAS assuming that the within group standard deviation will be 2.&#xD;
      The investigators will need to study 64 cases in each group to be able to reject the null&#xD;
      hypothesis that the population means of the Tramadol and Celecoxib are equal with probability&#xD;
      (power) 0.8. The investigators added 6 cases to each arm accounting for any missing data and&#xD;
      procedure failure ending in 70 cases in each group. The Type I error probability associated&#xD;
      with this test of this null hypothesis is 0.05 using Student's t test for independent&#xD;
      samples. Sample size calculation is done using Stats Direct statistical software version&#xD;
      2.7.2 for Windows, Stats Direct Ltd., Cheshire, UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain after IUD insertion</measure>
    <time_frame>one minute after IUD insertion</time_frame>
    <description>Women will mark a point corresponding to their pain on a visual analogue scale</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Tramadol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive oral Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) and an oral placebo similar to Celecoxib 2 hours before IUD insertion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive oral Celecoxib 200mg (Celebrex® 200, Pfizer, USA) and an oral placebo similar to Tramadol 2 hours before IUD insertion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women will receive a placebo similar to Tramadol and a placebo similar to Celecoxib orally 2 hours before IUD insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.</description>
    <arm_group_label>Tramadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.</description>
    <arm_group_label>Celecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1</intervention_name>
    <description>Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_label>Placebo 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 2</intervention_name>
    <description>Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.</description>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_label>Tramadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IUD</intervention_name>
    <description>IUD insertion</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_label>Tramadol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with expected difficult IUD insertion like nulliparous women and women with&#xD;
             previous cesarean section.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous vaginal delivery.&#xD;
&#xD;
          -  Submucous myoma.&#xD;
&#xD;
          -  Uterine anomalies.&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding.&#xD;
&#xD;
          -  Pelvic inflammatory disease.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbdelGany M Hassan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbdelGany M Hassan, MRCOG, MD</last_name>
    <phone>1017801604</phone>
    <email>abdelgany2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AbdelGany MA Hassan, MRCOG, MD</last_name>
      <phone>00217801604</phone>
      <email>abdelgany2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>AbdelGany MA Hassan, MRCOG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Kotb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Hassan A, Wahba A, Haggag H. Tramadol versus Celecoxib for reducing pain associated with outpatient hysteroscopy: a randomized double-blind placebo-controlled trial. Hum Reprod. 2016 Jan;31(1):60-6. doi: 10.1093/humrep/dev291. Epub 2015 Nov 29.</citation>
    <PMID>26621854</PMID>
  </reference>
  <reference>
    <citation>Kass-Wolff JH, Fisher JE. Evidence-based pain management for endometrial biopsies and IUD insertions. Nurse Pract. 2014 Mar 13;39(3):43-50. doi: 10.1097/01.NPR.0000434094.19101.d1. Review.</citation>
    <PMID>24535311</PMID>
  </reference>
  <reference>
    <citation>Scavuzzi A, Souza AS, Costa AA, Amorim MM. Misoprostol prior to inserting an intrauterine device in nulligravidas: a randomized clinical trial. Hum Reprod. 2013 Aug;28(8):2118-25. doi: 10.1093/humrep/det240. Epub 2013 Jun 5.</citation>
    <PMID>23739219</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 3, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>AbdelGany Hassan</investigator_full_name>
    <investigator_title>Lecturer of Gynecology and Obstetrics</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

